Clinical Trials

Inclusion criteria

• MGUS:
  • Age 40 years or older
  • Serum monoclonal protein greater than 1 g/dL, but less than or equal to 3 g/dL at the most recent clinic visit
  • Bone marrow plasma cells < 10 %
  • No end organ damage related to plasma cell dyscrasia including increased calcium concentration, lytic bone lesions, anemia, renal failure or a related B cell lymphoproliferative disorder.

• SMM:
  • Age 40 years or older
  • M-protein concentration of >3 g/dL
  • > 10% plasma cells in the bone marrow
  • No end organ damage (as above for MGUS)

• Newly diagnosed MM:
  • Age 40 years or older
  • Presence of a serum or urinary monoclonal protein
  • Presence of clonal plasma cells in the bone marrow or a plasmacytoma
  • Presence of end organ damage related to the plasma cell dyscrasia, such as increased calcium concentration, lytic bone lesions, anemia, or renal failure
  • Have not yet started treatment for MM, such as chemotherapy or bisphosphonate treatment

• Amyloidosis:
  • Age 40 years or older
  • Clinically confirmed amyloidosis (blood, urine, immunostaining, and/or mass spectroscopy)

• Controls:
  • Age 40 years or older

Exclusion criteria

• All groups
  • > stage IV renal disease
  • Treatment with any medications in the previous 12 months that can alter bone metabolism such as hormone replacement therapy, teriparatide, bisphosphonates, corticosteroids, sodium fluoride, calcitonin or antiepileptic drugs
  • Females that are pregnant or breastfeeding will not be allowed to participate